Abstract | CONTEXT: OBJECTIVE: We aimed to determine the expression of SSTRs 1, 2a, 3, and 5 in somatotroph adenomas, to correlate expression with clinical characteristics and the response to octreotide, and to ascertain whether preoperative octreotide treatment affected SSTR expression. DESIGN, SETTING, PATIENTS: The study included 78 adenomas from patients operated on consecutively during 2000 to 2010. After exclusion of 13 patients, immunohistochemical analysis with rabbit monoclonal antibodies against SSTRs 1, 2a, 3, and 5 (clones UMB-7, -1, -5, and -4) was performed on 65 adenomas. INTERVENTION: Twenty-eight patients received preoperative octreotide, and 37 patients were operated on without pretreatment. Twenty-six patients were randomized to direct surgery (n = 13) or to octreotide pretreatment (n = 13). MAIN OUTCOME MEASURE: SSTR expression was evaluated using a 12-grade scoring system. The responses to the octreotide test dose (GH reduction) and to 6 months of octreotide ( IGF-I reduction) were measured. RESULTS: The majority of adenomas showed membranous expression of SSTRs 2a and 5. SSTR2a expression was reduced in the pretreated group and correlated with the acute octreotide test results and the effect of octreotide treatment. In a linear regression model with SSTR2a expression as the determinant, the correlation with the acute test response improved after adjustment for medical pretreatment. CONCLUSION:
|
Authors | Olivera Casar-Borota, Ansgar Heck, Stefan Schulz, Jahn Marthin Nesland, Jon Ramm-Pettersen, Tove Lekva, Irina Alafuzoff, Jens Bollerslev |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 98
Issue 11
Pg. E1730-9
(Nov 2013)
ISSN: 1945-7197 [Electronic] United States |
PMID | 24092823
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents, Hormonal
- Receptors, Somatostatin
- somatostatin receptor 3
- somatostatin receptor type 1
- somatostatin receptor 5
- somatostatin receptor 2
- Octreotide
|
Topics |
- Acromegaly
(drug therapy, metabolism, surgery)
- Adenoma
(drug therapy, metabolism, surgery)
- Adult
- Animals
- Antibodies, Monoclonal
(pharmacology)
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Combined Modality Therapy
- Female
- Growth Hormone-Secreting Pituitary Adenoma
(drug therapy, metabolism, surgery)
- Humans
- Male
- Middle Aged
- Octreotide
(therapeutic use)
- Preoperative Care
(methods)
- Rabbits
- Receptors, Somatostatin
(immunology, metabolism)
- Time
- Treatment Outcome
|